0000000000025000

AUTHOR

Gallo P

showing 4 related works from this author

[The effect of instrumentation on original apical foramen shape using steel vs niti rotatory: computerized analysis]

2002

BACKGROUND. A fundamental requirement to obtain a correct endodontic preparation depends on the respect, during cleaning and shaping, of the original morphology of the apical foramen, (AF), so that the filling material will form a complete seal. METHODS. In our previous studies, in order to verify if this presumption was respected using rotary NiTi instruments with cutting tip, we instrumented extracted teeth characterised by a different degree of root curvatures. Using a standardized system to replace the sample, the original shape of the apical foramen of each tooth was recorded using a computerised technique and then compared to the shape after instrumentation. The data showed difference…

TitaniumTooth ApexSettore MED/28 - Malattie OdontostomatologicheNickelImage Interpretation Computer-AssistedHumansStainless Steelrotary NiTi instruments stainless steel instruments apical foramen shapeRoot Canal PreparationDental Alloys
researchProduct

Osseotite caricati a due mesi nei settori posteriori del mascellare superiore: controllo a 2 anni di due casi clinici

2003

Aim Acid etched surface implants determine high clinical success rates, but little information is available about early loading in the posterior region of the maxilla, area at risk of failure. The aim of this work is to present two case reports of oral rehabilitation through acid etched surface implants (Osseotite, Implant Innovations - 3i, West Palm Beach, FL) loaded two months after insertion in the posterior maxilla. Materials and methods The success of Osseotite implants was assessed 12 and 24 months after prosthetic loading according to Albrektsson et al. criteria (1986). Results No clinical or radiographic signs of implant failure were observed during the two years follow-up. Conclusi…

Acid-etched surfaces early loading posterior maxilla
researchProduct

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

2014

none 330 Women live longer and outnumber men. On the other hand, older women develop more chronic diseases and conditions such as arthritis, osteoporosis and depression, leading to a greater number of years of living with disabilities. The aim of this study was to describe whether or not there are gender differences in the demographic profile, disease distribution and outcome in a population of hospitalized elderly people.Retrospective observational study including all patients recruited for the REPOSI study in the year 2010. Analyses are referred to the whole group and gender categorization was applied.A total of 1380 hospitalized elderly subjects, 50.5\% women and 49.5\% men, were conside…

GerontologyMaleActivities of daily livingSettore MED/09 - Medicina InternaGeriatric MedicineComorbidityDisease distribution; Elderly; Sex-gender difference; In-hospital mortalityDisease distribution; Elderly; In-hospital mortalityElderlyRetrospective StudieDisease distributionActivities of Daily Livinggender80 and overDepression (differential diagnoses)Aged 80 and overeducation.field_of_studyhospitalized elderlyDepressionMortality rateMedicine (all)gender hospitalization elderlyHospitalizationIn-hospital mortalityItalyoutcomeGeriatric Depression ScaleFemaleInpatientHumanPopulationGender-differencesex-gender differencesFollow-Up StudieCognition DisorderDisease distributionmedicineInternal MedicineDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged; 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineHumansDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineSex DistributioneducationGeriatric AssessmentSex-gender differenceAgedRetrospective StudiesInpatientsbusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseaseComorbidityGender-differences; disease distribution; outcome; hospitalized elderlyIn-hospital mortalityElderlyMood disordersChronic DiseaseDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatientsdisease distribution; elderly; in-hospital mortality; sex-gender differencesMorbiditybusinessDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal Medicine; Medicine (all)Cognition DisordersFollow-Up Studies
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct